The endocrine society fights racism; Bisphosphonate holidays; Double brand Tirzepatide?


A political perspective of the endocrine society calls for new policies to address racial and ethnic inequalities in the endocrine workforce, as well as in access to care. “As endocrinologists, we have a responsibility to take action to eliminate racism in our discipline and for our patients,” said initiative chair, Ruban Dhaliwal, MD, MPH, of Massachusetts General Hospital in Boston. , in a press release. (Journal of Clinical Endocrinology and Metabolism)

Should transgender adolescents be required to undergo therapy before undergoing hormone therapy? (New York Times)

Women with more severe menopausal symptoms had lower cognitive performance than those with milder symptoms. This lower cognition was also linked to depression and sexual dysfunction. (Menopause)

For older adults on long-term osteoporosis treatment—especially 3 years or more—medication leave with risedronate (Actonel, Atelvia) was linked to a small but significantly higher risk of hip fracture compared to alendronate medication leave (Binosto, Fosamax). (Annals of Internal Medicine)

Eli Lilly is considering a similar dual-brand strategy in the future with its investigational GIP/GLP-1 agonist tirzepatide, as is Novo Nordisk’s strategy with semaglutide – Wegovy for obesity and Ozempic/Rybelsus for diabetes. (FiercePharma)

Rhythm Pharmaceuticals announced that the first patients in the DAYBREAK Phase II clinical trial received a weekly formulation of the MC4R agonist setmelanotide (Imcivree) for the treatment of severe obesity and overeating potentially caused by a genetic variant that alters the function of the MC4R pathway.

According to a new study in rats, the consumption of artificial sweeteners during pregnancy increases the risk of obesity in the offspring. “Even though the offspring never consumed the low-calorie sweeteners themselves, their gut bacteria and risk of obesity were influenced by the sweeteners consumed by their mothers during pregnancy,” the study author said. Raylene Reimer, PhD, of the University of Calgary, in a statement. . (Nutrition Frontiers)

And a similar study in female mice found that exposure to the endocrine disruptor BPA before and during pregnancy could affect fetal brain development. (Epigenomics)

  • Kristen Monaco is a writer, specializing in endocrinology, psychiatry and nephrology news. Based in the New York office, she has been with the company since 2015.


Comments are closed.